hashimoto disease and glp 1 Microdosing GLP-1 for Hashimoto's: Evidence, Risks NHS Guidance – Bolt Pharmacy Thyroid Cancer and GLP-1 Medications:

Design Defects: The drugs may be inherently dangerous due to how they interact with the bodys natural digestive and vascular systems

Jensterle M, Rizzo M, Haluzk M, Jane A

Physiologic replacement of both these incretin agents in the form of dual GLP-1/GIP receptor activating compounds (twincretins) has yielded encouraging results vis--vis glucose and body weight regulation

Nat Rev Cardiol 21(2):69 Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J et al (2025) Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial

The visible change is driven mainly by the magnitude and pace of weight loss